← Leaderboards
Craig D Rubin
University Of Texas Sw Med Ctr/Dallas
$2,077,007
Attributed
$2,077,007
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39.3K · FY2005–07$50K$37.5K$25K$12.5K$0
'05
'06
'07
Funding mix
By agency
NIH$2,077,007 · 6
By mechanism
M01$2,077,007 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Charles Y.c Pak$11,557,463
- Khashayar Sakhaee$14,492,169
- Nicola Abate$3,858,061
- Naim M Maalouf$8,442,081
- Margaret S. Pearle$3,288,901
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationOsteoporosisClinical ResearchHuman SubjectSkeletal Disorder ChemotherapyDrug Adverse EffectCitratesSlow Release DrugSodiumCalciumCalcium MetabolismBone DensityBone FractureDietary SupplementsDrug Screening /EvaluationFemaleFluorineFunctional AbilityHormone TherapyHuman Old Age (65+)Ingested Fluoride TherapyMetabolism Disorder ChemotherapyNutrition Of AgingNutrition Related Tag
Grant awards (13)
NEOSTEN AND ALENDRONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS$5,702
M01 · FY2007 · RR · contact PI
NEOSTEN AND ALENDRONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS$33,062
M01 · FY2006 · RR · contact PI
NEOSTEN AND ALENDRONATE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS$39,281
M01 · FY2005 · RR
Neosten and Alendronate in the Management of Postmenopausal Osteoporosis$35,880
M01 · FY2004 · RR
TREATMENT OF SENILE OSTEOPOROSIS$321,374
M01 · FY2002 · RR
USE OF GROWTH HORMONE FOR OSTEOPOROSIS OF WERNERS SYNDROME$321,374
M01 · FY2002 · RR
TREATMENT OF SENILE OSTEOPOROSIS--OPEN LABEL CROSSOVER STUDY$321,374
M01 · FY2002 · RR
USE OF GROWTH HORMONE FOR OSTEOPOROSIS OF WERNERS SYNDROME$321,374
M01 · FY2001 · RR
TREATMENT OF SENILE OSTEOPOROSIS$321,374
M01 · FY2001 · RR
TREATMENT OF SENILE OSTEOPOROSIS--OPEN LABEL CROSSOVER STUDY$321,374
M01 · FY2001 · RR
USE OF GROWTH HORMONE FOR OSTEOPOROSIS OF WERNERS SYNDROME$34,838
M01 · FY2000 · RR
TREATMENT OF SENILE OSTEOPOROSIS--OPEN LABEL CROSSOVER STUDY$0
M01 · FY2000 · RR
TREATMENT OF SENILE OSTEOPOROSIS$0
M01 · FY2000 · RR